This company provides structured, evidence-based psychedelic-assisted therapy for patients dealing with conditions like cancer-related distress, PTSD, depression, and trauma. They facilitate healing through clinical trials utilizing various psychedelic compounds under the supervision of trained medical professionals. Their focus is on establishing high standards for clinical care delivery in the psychedelic medicine space.
Funding
$11.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients facing cancer and complex mental health disorders often experience significant emotional suffering that can be difficult to treat with conventional methods. The limitations of traditional approaches can leave individuals feeling unsupported in addressing their holistic well-being.
Solution
Sunstone Therapies delivers psychedelic-assisted therapy within a medical framework to address the emotional and psychological challenges of individuals with cancer and complex mental health disorders. The company combines clinical trials with a highly-trained interdisciplinary team and purposely designed centers to provide a safe and compassionate setting for treatment. Sunstone's approach focuses on whole-person healing, integrating medical and psychological support to improve patient outcomes. They utilize compounds such as psilocybin and MDMA in conjunction with therapy to facilitate emotional processing and healing. Sunstone is committed to establishing the gold standard for psychedelic clinics to deliver care that reduces emotional suffering and makes safe, effective psychedelic-assisted therapy accessible.
Target Audience
The primary audience includes cancer patients and individuals with complex mental health disorders seeking innovative approaches to address emotional suffering, as well as providers looking to refer patients for psychedelic-assisted therapy.
Features
- Delivery of psychedelic-assisted therapy within a medical setting
- Utilization of compounds such as psilocybin, MDMA, LSD, 5-MeO-DMT, Methylone and RE104 (serotonergic antidepressant)
- Treatment for indications such as PTSD, MDD, TRD, GAD, Adjustment Disorder, Postpartum Depression, Palliative Care (End of Life), and Cancer & MDD
- Clinical trials to evaluate the safety and efficacy of psychedelic-assisted therapy
- Interdisciplinary team of trained therapists and medical professionals
- Integration of medical and psychological support for whole-person healing
- Centers designed to provide a safe and compassionate setting for treatment